eicosapentaenoic acid + docosahexaenoic acid (KD Pharma Group)

A combination of the long-chain omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) being evaluated for the treatment of major depressive disorder (MDD), specifically in pregnant women (antenatal MDD). EPA and DHA are essential fatty acids that play critical roles in brain function and inflammatory response. The therapeutic rationale for their use in depression involves the modulation of pro-inflammatory cytokines and the alteration of neuronal membrane composition and fluidity, which can influence neurotransmitter signaling pathways including serotonin and dopamine. This specific intervention, studied by William Coryell, investigates whether baseline cytokine activity and erythrocyte PUFA concentrations can serve as biomarkers to predict clinical response to supplementation, offering a potential non-pharmacological alternative for women who prefer to avoid conventional antidepressants during pregnancy.

Brand names

OceanBlue Omega-3 EPA+DHA

Other names

Omega-3 PUFA supplementationOmega3 PUFA supplementationOmega 3 PUFA supplementationEPA + DHAdocosahexaenoic acideicosapentaenoic acidOmega-3 fatty acidsOmega3 fatty acidsOmega 3 fatty acids